Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01429064 · ClinicalTrials.gov registry record · Phase 2
Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001
A Phase 2 study of Prostate Cancer, sponsored by Orion Corporation, Orion Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
- 17
- Study locations
NCT01429064: Completed Phase 2 study of Prostate Cancer, sponsored by Orion Corporation, Orion Pharma.
NCT01429064 is a Phase 2 study of Prostate Cancer that has completed, run by Orion Corporation, Orion Pharma. The registered enrollment target is 76 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (87% lower). The trial reports 17 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01429064, a Phase 2 study of Prostate Cancer, has completed, sponsored by Orion Corporation, Orion Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
- 17
- Study locations
Study Summary
The purpose of this study is to evaluate safety and tolerability of ODM-201 in patients with castrate resistant prostate cancer.
Primary Outcome
Adverse events from start of ODM-201 treatment (in ARADES 3104001 study) until end of study visit (in ARADES-EXT 3104002 study). Median duration on study treatment was 11,0 months.
Conditions Studied
Interventions
- DRUG ODM-201
Study Locations (17)
Other
- Klinika onkologie a radioterapie LFUK a FN - Hradec Králové
- East-Tallinn Central Hospital - Tallinn
- Helsinki University Central Hospital - Helsinki
- Kuopio University Hospital - Kuopio
- Oulu University Hospital - Oulu
- Tampere University Hospital - Tampere
- Turku University Hospital - Turku
- Saint Louis Hospital - Paris
- Institut Gustave Roussy - Villejuif
- Queen Elizabeth Hospital - Birmingham
- Velindre Cancer Centre - Cardiff
- Christie Hospital - Manchester
- Churchill Hospital - Oxford
Colorado
- The Urology Center of Colorado - Wheat Ridge
Connecticut
- Eastern CT Hematology and Oncology Associates - Norwich
Ohio
- Cleveland Clinic - Cleveland
South Carolina
- Carolina Urologic Research Center - Myrtle Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2011-06 |
| Est. Completion | 2015-11 |
| Phase | Phase 2 |
What the finished NCT01429064 record still lists
NCT01429064 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 76 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which ODM-201 is the first listed.
NCT01429064 lists 17 locations in 5 states (Other, Colorado, Connecticut).
Frequently Asked Questions
What is clinical trial NCT01429064 about?
NCT01429064 is a clinical study titled "Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001". The purpose of this study is to evaluate safety and tolerability of ODM-201 in patients with castrate resistant prostate cancer.
What is the current status of trial NCT01429064?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2011-06. Estimated completion is 2015-11.
What conditions does trial NCT01429064 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT01429064?
The interventions under investigation include: ODM-201 (DRUG).
Who is sponsoring clinical trial NCT01429064?
This trial is sponsored by Orion Corporation, Orion Pharma, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01429064 being conducted?
This trial has 17 study locations across Colorado, Connecticut, Ohio, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01429064's enrollment target sits among peer trials
76 388th of 735 higher than 345 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02615184 · 76 participants · Phase 2
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
- NCT02821741 · 76 participants · NA
Effects of External Ear Stimulation on Pain Perception and Mood
- NCT03019757 · 76 participants
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
- NCT03353584 · 76 participants · NA
Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia